Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Acquir Immune Defic Syndr ; 76(5): 512-521, 2017 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-29023251

RESUMO

BACKGROUND: Tuberculosis (TB) screening affords clinicians the opportunity to diagnose or exclude TB disease and initiate isoniazid preventive therapy (IPT) for people living with HIV (PLHIV). METHODS: We implemented an algorithm to diagnose or rule out TB among PLHIV in 11 HIV clinics in Thailand and Vietnam. We assessed algorithm yield and uptake of IPT and factors associated with TB disease among PLHIV. RESULTS: A total of 1448 PLHIV not yet on antiretroviral therapy (ART) were enrolled and screened for TB. Overall, 634 (44%) screened positive and 119 (8%) were diagnosed with TB; of these, 40% (48/119) were diagnosed by a positive culture following a negative sputum smear microscopy. In total, 55% of those eligible (263/477) started on IPT and of those, 75% (196/263) completed therapy. The prevalence of TB disease we observed in this study was 8.2% (8218 per 100,000 persons): 46 and 25 times the prevalence of TB in the general population in Thailand and Vietnam, respectively. Several factors were independently associated with TB disease including being underweight [aOR (95% CI): 2.3 (1.2 to 2.6)] and using injection drugs [aOR (95% CI): 2.9 (1.3 to 6.3)]. CONCLUSIONS: The high yield of TB disease diagnosed among PLHIV screened with the algorithm, and higher burden among PLHIV who inject drugs, underscores the need for innovative, tailored approaches to TB screening and prevention. As countries adopt test-and-start for antiretroviral therapy, TB screening, sensitive TB diagnostics, and IPT should be included in differentiated-care models for HIV to improve diagnosis and prevention of TB among PLHIV.


Assuntos
Antituberculosos/uso terapêutico , Infecções por HIV/complicações , Isoniazida/uso terapêutico , Tuberculose/diagnóstico , Tuberculose/prevenção & controle , Adolescente , Adulto , Algoritmos , Antituberculosos/administração & dosagem , Controle de Doenças Transmissíveis/métodos , Controle de Doenças Transmissíveis/organização & administração , Feminino , Humanos , Isoniazida/administração & dosagem , Masculino , Tailândia/epidemiologia , Tuberculose/epidemiologia , Vietnã/epidemiologia , Adulto Jovem
2.
Clin Infect Dis ; 35(6): 769-72, 2002 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-12203177

RESUMO

We conducted a trial of oral acetazolamide for the treatment of cryptococcal meningitis in 22 Thai adults with headache and an opening cerebrospinal fluid pressure of >/=200 mm H(2)0. The trial was terminated prematurely because patients who received acetazolamide developed significantly lower venous bicarbonate levels and higher chloride levels and had more-frequent serious adverse events than did subjects who received placebo.


Assuntos
Acetazolamida/uso terapêutico , Hipertensão Intracraniana/tratamento farmacológico , Meningite Criptocócica/complicações , Acidose/etiologia , Administração Oral , Adulto , Anfotericina B/uso terapêutico , Antifúngicos/uso terapêutico , Diuréticos/uso terapêutico , Método Duplo-Cego , Feminino , Cefaleia/tratamento farmacológico , Humanos , Hipopotassemia/etiologia , Hipertensão Intracraniana/etiologia , Masculino , Meningite Criptocócica/tratamento farmacológico , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa